RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

Launched by AGNOVOS HEALTHCARE, LLC · Mar 11, 2021

Keywords

ClinConnect Summary

The RESTORE trial is studying a medication called AGN1 to see if it can help prevent additional hip fractures in older women who have already suffered a hip fracture due to weak bones (a condition known as osteoporosis). The trial will involve up to 2,400 women aged 65 and older who have recently had a low-energy hip fracture and will be undergoing surgery to repair it. To participate, women must have certain risk factors for future fractures, such as a history of falls, cognitive issues, or other health conditions that make them more vulnerable.

Participants in the trial will be randomly assigned to receive either the AGN1 treatment or a placebo (a non-active substance) and will be followed for at least five years after their surgery. This long follow-up is important to see how well the medication works in preventing further fractures. The study is currently recruiting participants, and those who join will be closely monitored throughout the process to ensure their safety and gather important data on the effectiveness of the treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age.
• • 2. Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
• 3. Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):
• • Documented falls assessment indicating subject is at moderate or high risk of falls
• • Falls history (2 or more falls in the previous 12 months)
• • History of vertigo, dizziness, or postural hypotension
• • Documented T-score \< -2.5 at the hip
• • Taking more than 3 daily prescription medications
• * Visual impairment as confirmed by one of the following:
• • Subject reports difficulty seeing
• • Lack of depth perception or vision loss in one eye
• • Macular degeneration
• • Cataracts
• • Prior non-hip fragility fracture
• • Cognitive frailty as assessed by SPMSQ (mild or moderate cognitive impairment) or delirium
• • Parkinson's disease stage 3 or 4
• • 10-year hip fracture probability \>15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country
• • 4. Subject is expected to be ambulatory after the hip fracture repair procedure.
• • 5. Informed consent is provided by the subject or the subject's LAR.
• • 6. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.
• Exclusion Criteria:
• • 1. Subject hospital admission is \> 24 hours from the time of the index hip fracture.
• • 2. Subject was dependent on the use of a wheelchair or was bedridden prior to the index hip fracture.
• • 3. Subject is currently enrolled in another clinical study.
• • 4. Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.
• • 5. Subject has one or more new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, and/or recovery or subject has three or more new fractures in addition to the index hip fracture.
• • 6. Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.
• • 7. Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.
• • 8. Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures.
• • 9. Subject is at ASA Class IV, V, or VI.
• • 10. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
• • 11. Subject has a history of Pott's disease.
• • 12. Subject has a history of any invasive malignancy (except nonmelanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for 5 years.
• • 13. Subject has chronic cardiac insufficiency or severe cardiovascular disease as assessed by a subject or LAR interview to be NYHA Class III or IV or has an implanted pacemaker.
• • 14. Subject has a history of cardiovascular events (e.g. stroke, transient ischemic attack, myocardial infarction, unstable angina, pulmonary embolus, deep vein thrombosis, ventricular tachycardia, or atrial fibrillation) in the last 3 months.
• • 15. Subject is on oral or parenteral immuno-suppressive drugs.
• • 16. Subject has uncontrolled diabetes mellitus.
• • 17. Subject has Hb ≤ 9 g/dL at admission.
• • 18. Subject has severe renal insufficiency defined as an estimated glomerular filtration rate (eGFR) ≤ 30 mL/min.
• • 19. Subject has a diagnosed and ongoing calcium metabolism disorder.
• • 20. Subject has a Parker Mobility Score ≤ 5.
• • 21. Subject has severe cognitive impairment as assessed by SPMSQ.
• • 22. Subject has known allergies to calcium-based bone void fillers.
• • 23. In the judgement of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues).
• • 24. Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.